Lung Cancer
From the Journals
Opioids after lung cancer surgery may up all-cause mortality risk
“New long-term opioid use may be associated with poor long-term survival outcomes, especially in potent opioid users.”
Conference Coverage
In NSCLC, not all EGFR mutations are the same
Patients with the Ex20 insertion may buck trend by responding well to ICIs.
Conference Coverage
In early NSCLC, comorbidities linked to survival
Respiratory and cardiometabolic comorbidities were associated with significantly worse overall survival in lung cancer.
Conference Coverage
‘Smoking gun–level’ evidence found linking air pollution with lung cancer
The finding could lead to strategies for preventing lung cancer in nonsmokers exposed to high levels of foul air.
Conference Coverage
Gene mutations may drive lung cancer in never-smokers
Study hints at mechanistic differences between small cell lung cancer in smokers versus nonsmokers.
From the Journals
Nearly 30% of U.S. cancer deaths linked to smoking
Getting more people to screen for lung cancer in the United States is also important, given that only 6.6% of eligible people in 2019 received...
From the Journals
Lung adverse effects in patients taking trastuzumab deruxtecan
Close monitoring and proactive management may reduce the risk of ILD.
Conference Coverage
A look at lung cancer screening in resource-limited countries
Interim report from IASLC highlights unique challenges faced by low- and middle-income countries.
Conference Coverage
How common are second primary lung cancers?
New study estimated risk and found that more elapsed time was associated with later stage at diagnosis.
News from the FDA/CDC
FDA approves Enhertu (trastuzumab deruxtecan) for HER2 lung cancer
“These results establish the new standard of care for patients with NSCLC harboring HER2 mutations.”